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Abstract: Cancer research has been heavily geared towards genomic events in the development
and progression of cancer. In contrast, metabolic regulation, such as aberrant metabolism in
cancer, is poorly understood. Alteration in cellular metabolism was once regarded simply as a
consequence of cancer rather than as playing a primary role in cancer promotion and maintenance.
Resurgence of cancer metabolism research has identified critical metabolic reprogramming events
within biosynthetic and bioenergetic pathways needed to fulfill the requirements of cancer cell growth
and maintenance. The tumor suppressor protein p53 is emerging as a key regulator of metabolic
processes and metabolic reprogramming in cancer cells—balancing the pendulum between cell death
and survival. This review provides an overview of the classical and emerging non-classical tumor
suppressor roles of p53 in regulating mitochondrial dynamics: mitochondrial engagement in cell
death processes in the prevention of cancer. On the other hand, we discuss p53 as a key metabolic
switch in cellular function and survival. The focus is then on the conceivable roles of p53 in breast
cancer metabolism. Understanding the metabolic functions of p53 within breast cancer metabolism
will, in due course, reveal critical metabolic hotspots that cancers advantageously re-engineer for
sustenance. Illustration of these events will pave the way for finding novel therapeutics that target
cancer metabolism and serve to overcome the breast cancer burden.
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1. Introduction
Nicknamed the “Guardian of the Genome,” p53 (encoded by the TP53 gene) is believably the
most extensively studied and most multifaceted tumor suppressor protein identified to date [1–3].
The role of p53 extends well beyond its role as a tumor suppressor; it is emerging as an important
regulator of metabolic homeostasis, pivotal in most major cellular processes [1,4–8]. In the breast p53
plays a fundamental role in cell homeostasis: maintaining metabolic homeostasis during pregnancy,
providing a protective role against latent breast cancer [9], and its more classical roles of protecting
the genome, DNA repair, and/or programmed cell death [10]. Critical mutations in the TP53 gene
are common in most cancers and major contributors to cancer progression. In contrast, the majority
of breast cancers harbor wild-type p53 (wt-p53), though in most cases the protein is non-functional,
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in part due to loss of upstream regulators in the p53 pathway [11]. Classical thinking supports that
reinstating the p53 pathway may be one avenue of more efficacious breast cancer treatment through
p53 activation of programmed cell death pathways. This concept may be flawed due to the poorly
understood role of p53 in cellular metabolism, which is currently being widely revisited.
Originally, altered metabolism was deemed to be merely a byproduct of cancer, rather than
being considered as playing an intricate role in its support and maintenance. In the last
decade, however, the resurgence of cancer metabolism research has increased exponentially. Cancer
metabolism is now being viewed as a series of critical metabolic reprogramming events within
biosynthetic and bioenergetic pathways, needed to fulfil the requirements of cancer cell growth and
maintenance [1,12–14]. Renewed focus on cancer metabolism has identified the tumor suppressor
protein, p53, as a key regulator of metabolic processes and metabolic programming [1,15–17].
This review firstly provides a brief understanding of ongoing problems with breast cancer therapy.
Next, we provide an overview of the classical and non-classical roles of p53 focusing in on the emerging,
critical roles of p53 in metabolic reprogramming. On one hand, p53 engages in mitochondrial cell
death processes in the prevention and treatment of cancer, and on the other hand it plays an important
role in cell survival and function, hence ‘balancing the pendulum between cell death and survival’.
Further, we bring back the discussion to how these p53-reprogramming events may be important in
cell survival and provide new avenues for breast cancer therapies.
1.1. Overview of Breast Cancer
Breast cancer is the most commonly diagnosed cancer and cause of cancer deaths among women
worldwide: an estimated 1.7 million cases were diagnosed in 2014, accounting for 25% of all cancers in
women [18]. One in eight women will develop breast cancer in their lifetime [19,20]. Upon diagnosis,
breast cancers are categorized into subtypes that are defined based on their stage of progression, level of
invasiveness, and hormonal receptor status [21–23]. There are three distinct classes of hormone receptor
profiles that are typically overexpressed and highly dysregulated in breast cancer. These include:
(1) the estrogen receptor (ERα)/progesterone receptor (PR); (2) human epidermal growth factor
receptor 2 (HER2); and (3) triple-negative breast cancers (TNBC) that do not express any of these
three receptors [21–23]. The prevalence of each of these subclasses and their typical treatments are
summarized in Table 1. Common treatment regimes for breast cancer include surgical ablation,
adjuvant or neoadjuvant chemotherapy, radiotherapy, and endocrine therapy, with the therapeutic
strategy dependent on the stage and type of cancer [24]. Radiotherapy and chemotherapy induce DNA
damage, inducing cell cycle arrest and apoptosis [25–28]. Endocrine therapy, including Tamoxifen and
Fulvestrant, blocks the ERα receptor, which in turn represses aberrant estrogen signaling [21]. Similarly,
targeted therapies like Trastuzumab target the overexpression of HER2 [21,29], while aromatase
inhibitors inhibit the synthesis of estrogen [21,30].
Table 1. Major breast cancer receptor sub-types and standard therapies.
Receptor Status [21,31] Prevalence (%) Endogenous Ligand Standard Therapy Type
ERα+/PR+ 70–80% Estradiol/Progesterone Endocrine Therapy
HER2+ 15–20% EGF, TGF-α HER2-targeted Therapy
TNBC 15% - Chemotherapy/Radiotherapy
Note: ER, PR, and HER2 receptors are listed alongside their associated prevalence in breast cancers. TNBC refers to
an absence of all three receptor types; this tumor type is notoriously difficult to treat [32]. The typical endogenous
binding ligands and treatment type are also shown with the respective receptor profile.
1.2. Breast Cancer Treatment Resistance and Recurrence
Current therapeutics, used alone or in combination, have been successful in the treatment of
breast cancer, with favorable increases in overall survival in recent decades [33]. Unfortunately,
a major challenge involves a large proportion of breast cancer patients developing resistance to these
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treatments (50% of ERα+/PR+ breast cancer, which comprises 70–80% of all breast cancers, inevitably
recur) [21,34,35]. Resistance leads to the recurrence of more aggressive secondary tumors [36,37],
stressing the need for further research into the fundamental cellular mechanisms that promote breast
cancer tumorigenesis, resistance, and recurrence. More recently, targeting dysregulated metabolism
is a reemerging area of cancer research. Metabolic reprogramming is now being recognized as a
cancer hallmark.
To date, breast cancer research has been heavily focused on exploring the contributions of
hyperactive growth and hormone receptor signaling, inherited and sporadic gene mutations, oncogene
amplification, loss of tumor suppressor proteins, and cancer heterogeneity in the development and
progression of breast cancer. For instance, mutations in the breast cancer genes BRCA1 and BRCA2
as well as the TP53 gene have all been well characterized in breast cancer [38–41]. Aberrations in
the P13K/AKT signaling pathway, which regulates the cell cycle and cell proliferation, are also well
documented [42]. In contrast, aberrant metabolism, as a contributing factor to the onset, progression,
and maintenance of breast cancer, is poorly understood.
In contrast to most cancers, mutations in the TP53 gene are only present in 20–30% of all breast
cancers, suggesting that p53 function is compromised [43,44] (discussed in Section 4). Alongside
its well-recognized role as a tumor suppressor, p53 has emerged as a major regulator of metabolic
processes and metabolic programming and is intrinsically linked with mitochondria and mitochondrial
dynamics associated with cell survival [1,15–17,45]. Further, more and more evidence is emerging
to suggest an association between drug resistance and dysregulated cellular metabolism [46]. In the
normal breast, during pregnancy p53 plays a key role in the reprogramming of breast cell function and
is strongly associated with protection against latent breast cancer. However, it is also associated with
the seeding of latent breast cancer, as reviewed in [9].
What key knowledge are we missing regarding the role p53 plays as the ‘guardian of metabolism’
that will help us understand breast cancer development, survival, resistance to treatment, and impact
on breast cancer recurrence?
2. The Multifaceted Tumor Suppressor Roles of p53
The p53 protein is a transcriptional regulator that is stabilized within the nucleus upon DNA
damage or oncogenic signaling. p53 regulates genes involved in cell cycle arrest, cell death (apoptosis),
DNA repair, and senescence to prevent tumor development and growth [3,5,47–51]. p53 also localizes
to the cytoplasm and the mitochondria, where it can regulate cytoplasmic cellular functions including
apoptosis. Non-canonical functions of p53, including necrosis [52], autophagy [53], and the less
well-known functions of p53, necroptosis (inflammatory programmed cell death) [54] and ferroptosis
(iron- and lipid-mediated cell death), have all been shown to be p53-activated specialized forms of
mitochondria-programmed cell death processes [5,50,51]. Critical mutations in p53 can prevent its
anti-tumor functions and/or enhance oncogenicity [55,56]. All these p53 functions, which are briefly
discussed as part of this review, are clearly directed towards the physiology of removing abnormal
cells and prevention of tumorigenesis. Additional less characterized p53-associated processes that
do not necessarily lead to cell death include autophagy, senescence, differentiation, and dormancy.
In recent years, mounting evidence has also implicated p53 as a central player in the regulation of
cellular energy metabolism [1,10,15–17], alongside potential roles in the regulation of mitochondrial
dynamics, beyond cell death [57–59]. Homeostasis regulation of the mitochondrial DNA involves
both p53-nuclear transcriptional target genes, whose products translocate to the mitochondria or
non-nuclear direct cytoplasmic effects of the p53 protein.
2.1. Canonical and Non-Canonical Functions of p53 in Cancer Protection
Much of the p53 literature is directed towards the well-characterized canonical tumor suppressor
protective roles of p53, which are typically impaired upon mutation or deletion, leading to the
production of many of its oncogenic forms [15,39,60]. Oncogenic p53 mutations, resulting in change
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or loss of function, are found in approximately 50% of all human cancers, making it one of the most
frequently mutated proteins in cancer [39,61]. From its widespread transcriptional factor activity,
p53 has the ability to activate the expression of genes associated with cell cycle arrest, cell death,
DNA repair, and cell abeyance, which occurs in response to a range of cellular stress signals that
post-translationally activate p53 (Figure 1) [48,53,62,63].
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single-stranded break repair and the repair of other DNA lesions within the genome to prevent genomic
instability. Paradoxically, it is mutations in the p53 gene itself that lead to tumor formation.
2.1.2. Apoptosis
One of the most well-recognized canonical p53 programmed cell death pathways is apoptosis.
Nuclear p53 regulates genes associated with apoptosis in response to cellular stress signals via the
classical mitochondrial apoptotic pathway [49]. The primary mechanism by which p53 induces
apoptosis is transcriptional regulation of the pro-apoptotic proteins NOXA and p53-upegulated
modulator of apoptosis [72–74]. An additional mechanism by which p53 induces apoptosis is
direct translocation to the mitochondria, activating the mitochondrial apoptotic regulator BAX [75].
This implies that p53 mediates apoptosis both by transcriptional and post-translational mechanisms.
However, the question of how p53 activation induces apoptosis outside of its other well-known cellular
fate functions remains unclear. One proposal highlights that p53 may need to reach an “apoptotic
threshold” that overrides other functions to correspondingly promote apoptosis [49]. Other studies
suggest that the strength, duration of activation, sub-cellular location, and environmental co-factors of
p53 play key roles in determining the downstream outcomes of p53 activation [48,49,76].
2.1.3. Necrosis
Necrosis was once regarded as uncontrolled or ‘accidental’ cell death. This idea has been
superseded; necrosis is now regarded as a process of irreversible programmed cell death where
apoptosis has failed and can also be triggered by p53 [52,64,77]. Necrosis is a caspase-independent
pathway requiring receptor interaction protein kinases 1 and 3 (RIP1 and 3) and can be mediated
by p53 [54,78]. Subsequently, this action directly or indirectly affects mitochondria through NADPH
oxidase-derived ROS. The terms of necrosis have extended to include programmed necrosis, regulated
necrosis and necroptosis. Necroptosis is a relatively new concept, which is a combination of necrosis
and apoptosis-mediated p53 cell death and contributes to immune system regulation, contributing to
managing cells during inflammation, tissue injury, and other organismal stresses such as pathogen
infection [78,79].
2.1.4. Autophagy
The definition of autophagy, from an ancient Greek word, is ‘self-devouring’. Autophagy is an
evolutionarily conserved, genetically mapped process that forms the “recycling facility” of the cell.
This is a normal process in the cell to maintain homeostasis through programmed protein degradation
and turnover of organelles within the cell. This allows the cell to degrade organelles and proteins to
functional building units to fuel bioenergetic and biosynthetic processes [80]; alternatively, cancer cells
can undergo autophagy as a mechanism of cell death [81]. This catabolic pathway, involved in both
normal cell physiology and cancer pathophysiology, is modulated by p53-dependent mechanisms,
which is dependent on p53 cellular localization [82–85]. Within this context, p53 is seen to have
a dual/paradoxical role in regulating autophagy. On the one hand, the nuclear p53 function has
been shown to transcriptionally activate pro-autophagy genes; conversely, its cytoplasmic role shows
evidence of negatively regulating autophagy [82,83,85]. Therefore, the cellular context and environment
determines the role of p53 in autophagy signaling pathways. Autophagy is also important in selective
degradation of mitochondria (mitophagy) in mitochondria quality control [86]. In cancer, autophagy
has a controversial role, and is associated with interventions to both stimulate and inhibit cancer, as
debated in the recent review by Thorburn [87].
2.1.5. Dormancy
Perhaps one of the most under-researched roles of p53 is dormancy. It has been suggested that
dormancy may be viewed as a natural byproduct of evolutionary mechanisms, where dormant cells
are present in both healthy individuals and survivors of cancer [88]. The dormant cell minimizes
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energy expenditure to survive in adverse conditions. Mitochondria undergo active to deactivate
transition; however, the exact mechanism of this transition is unclear [89]. In breast cancer the concept
of cancer dormancy is particularly relevant given that most breast cancers are seeded early in life
and yet only manifest in later years. Many years after seemingly successful breast cancer treatment,
20–50% of breast cancers recur, believed to reemerge from remnant dormant cells from the original
tumor [90,91]. How this is achieved is unknown. Autophagy has been suggested as one of the key
processes to long-term cancer survival, allowing stressed cells to remain dormant yet viable in order
to survive and eventually regrow and relapse [91,92]. An additional theory is that tumor dormancy
results from tumor cells reaching a differentiated state [91]. In our laboratory we have shown that p53
can induce a dormant state in breast cancer cells, which has features of differentiation or senescent-like
morphology [59,93,94]. We also demonstrated that these breast cancer cells can remain viable for
many weeks in cell culture after p53-induced cell cycle arrest and eventually multiply by a process of
endoreplication or nuclear replication without mitosis [93]. Endoreplication may be one method by
which breast cancer cells escape dormancy and become more aggressive.
2.1.6. Cellular Senescence or Quiescence or Dormancy
p53 is a decision maker in cellular senescence, quiescence, or dormancy. Senescence is defined as
a state of irreversible cell cycle arrest in which cells display an inability to proliferate or respond to
growth factors [95–98]. In vivo studies highlight the pivotal role that p53-induced senescence plays in
tumor suppression [95,98]. Quiescence, a prolonged cell cycle arrest and attenuated cellular activity
at the G0–G1 phase, is also mediated by p53 [99,100]. Alternatively, dormancy is not unheard of in
terms of breast cancer recurrence, with 20–50% of all breast cancers recurring from years to decades
post treatment [35,90]. A common attempt to explain dormancy arises from models of both senescence
and quiescence, both mediated by p53. However, understanding the paradox of how these potentially
overlapping, and supposedly anti-tumorigenic functions facilitate dormancy and lead to recurrence
remains incomplete [91]. One potentially unidentified area to be investigated involves the effects of
p53 within cancer metabolism throughout and leading up to the point of recurrence.
2.1.7. Ferroptosis
Only discovered in 2012, ferroptosis is a novel non-apoptotic form of cell death, characterized
by lethal iron-dependent accumulation of lipid ROS, in a caspase-independent manner [101].
Morphologically, cells undergoing ferroptosis cell death are distinguished by small mitochondria
with condensed membrane density. Dixon and colleagues discovered that ferroptosis action can
be blocked or reversed by ferrostatin (Fer-1) in cancer cells [101]. Fer-1 has been shown to reverse
ferroptosis action through increasing the mitochondrial membrane potential and decreasing ROS
accumulation [102]. To investigate the process of ferroptosis, Gu and colleagues generated a mouse
model (named p53) that was unable to undergo p53-dependent cell cycle arrest, apoptosis and
senescence, but was still able to regulate p53-dependent changes in energy metabolism and ROS
production [103]. This suggested that the p53 associated energy metabolism and ROS functions were
disconnected from conventional cell cycle arrest and death mechanisms. Specific p53 target genes
have been identified as important in p53-directed ferroptosis including solute carrier family 7 member
11, a cysteine-glutamate exchanger, glutamase 2 (GLS2), prostaglandin-endoperoxide synthase 2,
and spermidine/spermine N1-acetytransferase1 [5]. This unique form of cell death is implicated in
multiple disease states including cancer [50].
In summary, mitochondria are core powerhouses for metabolic reactions that drive cellular
reprogramming through diverse pathways and mechanisms. Classical roads in p53 tumor
suppression lead to mitochondrial de-regulation or inactivity, whether it be for cell destruction or
temporary/permanent inactivation, respectively. Alternatively, p53 is linked to the quality control
mechanisms of the mitochondria and its genome, with projected roles in the organelle fusion–fission
process (discussed in Section 3.4) and supporting cell survival.
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3. Emerging Roles of p53 in Cancer Metabolism
Alteration in cancer cell metabolism is now considered a hallmark of cancer, whereby the
metabolic signatures of cancer cells are distinctly different from normal tissue [12,14,104–106].
These observed differences reflect metabolic changes that strategically fuel the requirements for
tumor development. p53 has emerging roles in counteracting the changes that occur in the metabolism
of cancer cells through regulation of several metabolic targets [1,10,15–17].
3.1. Metabolic Reprogramming for Cellular Proliferation
Cellular division requires an adequate biomass to produce two identical daughter cells.
This growth imposes a metabolic burden, requiring the cell to increase its energy supply to meet
the requirements for proliferation [13,107]. In cancer, the normal regulatory checkpoints within
cellular division are lost, permitting the cell to unceasingly proliferate [108]. Re-engineering of
fundamental metabolic pathways and nutrient uptake mechanisms often occurs to support this
uncontrolled proliferation. This ‘metabolic switch’ or metabolic reprogramming provides inherent
growth advantages in fulfilling the requirements of cancer cells [12–14,104]. These alterations include:
(1) restructuring the key metabolic pathways involved in glucose catabolism; (2) maintaining the
nutrient uptake mechanisms to meet metabolic demands; and (3) quickly replenishing anabolic
substrates needed for biosynthetic pathways (anaplerosis) such as nucleotide, protein, and lipid
synthesis [12–14,104]. These observations stem from a fundamental metabolic switch, formally
known as the Warburg effect (described in Section 3.2), whereby cancer cells show high dependence
on glycolysis and attenuated mitochondrial respiration [106,109,110]. To provide this demand for
glucose, cancer cells typically overexpress glucose transporters, supporting glucose flux [111,112].
This reliance on glycolysis, however, is not sufficient for cellular replication. Instead, principal
anabolic substrates found within and entering the tricarboxylic acid (TCA) cycle serve as hybrid
intermediates, forming the building blocks needed for proliferation [113]. One of these includes the
reliance of cancer cells on glutamine, which is converted to α-ketoglutarate within the TCA cycle [113].
Furthermore, cancer proliferation requires increased fatty acid synthesis for membranes and lipid
molecules. As such, controlling fatty acid synthesis has been proposed as a potential therapeutic
strategy [114,115]. Collectively, these metabolic strategies are employed to support cancer growth and
maintenance and, without such adaptive strategies, cancer cells will likely undergo apoptosis.
Now considered a hallmark of cancer, aberrant metabolism in cancer is re-emerging as an
area of intense research. As such, rectifying this aberrant metabolism is an appealing potential
cancer treatment. It is expected that intervention leading to interference with cancer cell metabolism
would form a successful treatment strategy. Before the development of a treatment strategy based
on metabolism intervention, a deep understanding of how cancer metabolism is reprogrammed and
regulated is needed. Recently, the tumor suppressor p53 has been implicated as a master regulator of
metabolism [1,10,15–17]; therefore, understanding the role of p53 in the regulation of cellular metabolic
processes may provide further avenues for the future treatment of cancer.
3.2. The Warburg/Weinhouse Debate
The Metabolic Switch. The concept of cancer metabolic switching from oxidative phosphorylation
to glycolysis (Figure 2) was first introduced by Otto Warburg in 1930 [106,109,110]. This shift in
cellular metabolism to a dominant glycolytic state, termed “The Warburg Effect” (aerobic glycolysis),
is unexpected as glycolysis is preferentially utilized over mitochondrial respiration, a mechanism that
supplies more energy, irrespective of the presence of oxygen [106,109,110].
Since then, the Warburg effect has been extensively studied, with many proposals attempting to
reveal both its origins and its promotion of tumorigenesis [106,109,110]. Originally, Warburg proposed
that damage to mitochondrial respiration (OXPHOS) in all cancers is sufficient for a malignant
glycolytic state, thus tumorigenesis is facilitated [116]. It is argued that the silencing of mitochondrial
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respiration, leading to the Warburg effect, is dependent on somatic and hereditary mutations in
both nuclear and mitochondrial DNA (mtDNA) [109]. Tumor-promoting mutations have been
found in mitochondrial encoded genes within prostate cancers and head and neck tumors [117,118].
Furthermore, nuclear DNA mutations in a number of mitochondria-specific metabolic enzymes
have been shown to facilitate tumorigenesis, leading to the formation of paragangliomas and
pheochromocytomas [119,120]. However, these mutations are considered rare, and are not associated
with more commonly occurring cancers such as breast cancer [109]. The Warburg theory has been
hotly debated and there is no sound experimental evidence that mitochondrial metabolism is impaired
in all cancer cells [121–123]. Apart from a limited range of rare cancers, damage to mitochondrial
respiration is not the driver of the glycolytic shift; in fact, many cancers exhibiting the Warburg effect
have been shown to retain functional mitochondria (normal OXPHOS) [109]. A biochemist, Sidney
Weinhouse, a pioneer in metabolic biochemistry, found that the cancer cell was able to oxide glucose
and fatty acids at a similar rate to normal cells [124]. One early explanation was that anaerobic
glycolysis was so high in tumor cells that it eliminated the need for oxidative respiration [121]. Hence a
chicken-and-egg analogy [125]. Did the mitochondrial dysfunction occur first, pushing the cell to
preferentially use glycolysis? Alternatively, did an increased flux in glycolysis occur first, thereby
repressing oxidative respiration? Neither viewpoint has been shown to be right or wrong, and this
conundrum is discussed in detail in the review by Senyilmaz and Teleman [125]. There is some
evidence to suggest that the glycolytic phenotype is characteristic of highly proliferating cells, whereas
the switch to oxidative respiration occurs during differentiation [126]. This explanation is in line with
our research, which shows that induction of p53 blocks the cell cycle and increases both oxidative
respiration and mitochondria biogenesis in breast cancer cells [59,93].
As damage to mitochondrial respiration does not appear to be the cause of glycolytic metabolic
dominance, the question is: What are the crucial drivers in the manifestation of Warburg’s original
observations? High mitochondrial activity and a dependence on mitochondrial and glycolysis
metabolism have been shown to be essential for the rapid proliferation of tumors [127,128].
3.3. How Does p53 Regulate Cancer Metabolism?
A loss of tumor suppressor proteins, oncogenic mutations within glucose metabolism, and changes
in the tumor microenvironment serve as the key drivers of metabolic reprogramming of aerobic
glycolysis [12,129–132]. It is only in the last 10–15 years that the link between p53 and aberrant
metabolism has been suggested [1,10,15–17,107]. As discussed above (Sections 3.1 and 3.2), enhanced
aerobic glycolysis and attenuated mitochondrial respiration facilitate cancer proliferation via energy
production and biosynthetic pathways. As summarized in Figure 2, p53 has been shown to
downregulate a number of critical components of the glycolytic pathway, including glucose entry
into cells [1,4]. The net result of p53 activation appears to be the inhibition of the overproduction of
pyruvate, the end product of glycolysis, and the promotion of mitochondrial respiration, as exhibited
within normal tissue. Typically, cancers preferentially convert this build-up of pyruvate to lactate,
but it can be converted to acetyl-CoA by lactate dehydrogenase and pyruvate dehydrogenase (PDH),
respectively [10]. p53 has been shown to negatively regulate mitochondrial PDH 2, which increases
PDH activity, thus promoting the conversion of pyruvate to acetyl-CoA instead of lactate, encouraging
the TCA cycle, and enhancing mitochondrial respiration [10]. p53 has also been shown to regulate fatty
acid oxidation (FAO) by facilitating the transport of fatty acids into the mitochondria via activation
of carnitine palmitoyltransferase 1C and by positively regulating the β-oxidation of fatty acids in
response to nutrient stress [10]. This ability of p53 to increase FAO promotes NADH and FADH2
production, which enhances OXPHOS [10].
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i r . p53 balances gl colysis and mitochondrial respiration. The roles of p53 in cancer
metabolism include: (A) suppre sing the first step of glycolysis by direct downreg lation of
glucose-type transporters (GLUT) including GLUT 1, GLUT3, and GLUT4 receptors, which re
typically overexpress d in the membranes of cancer cells to facilitate glucose flux [ 10,1 3]; ( ) i
l ti f l l i
( ) r latio f l t i ase-2, lea i g t i s i i .
ro otes t e c cle it c rial res iration [134]. l ti f
i ( c l , i tar eti t c t c r c oxi as asse l r tei , i cre
it c ondrial respiration. COX is a vital transmembrane protein that accepts oxygen in mit chondrial
respiration [17]. This figure has been adapted from [1].
Cancer cells typically increase fatty acid uptake and synthesis to meet the demands of membrane
biosynthesis, and p53 has been shown to oppose this effect. In contrast, early literature suggests
p53 promotes glycolysis in a tissue- and context-specific manner, where p53 is activated to rectify
a metabolic stress [135,136]. These include the positive regulation of enzymes that control the first
rate-limiting step of glycolysis, such as hexokinase II (HK2), by p53 [135,136]. More recently, p53 has
been shown to play a crucial role in re-aligning metabolic homeostasis to ensure cell survival during
nutrient deprivation [137]. These examples shed light on an emerging view of p53 as a metabolic
homeostatic regulator in both normal and cancerous tissue, and not solely as a mediator of the
glycolysis and OXPHOS metabolic balance [10].
. . it i l i
t i i t li t i t l li t ti it f t r s r t i
, t l it i l l ti . i i l t lli it i l i ,
shape through fusion and fission events and intracellular transp rtation [138,139].
These mechanisms, known as mitochondrial dynamics, ensure optimal mitochondrial bioenergetic
functi n to accommodate energy demands of the cell [140,141]. Mitochondrial dynamics has been
observed to be influenced by p53 [57,59,142].
r l f it ri i i ti t l li t t ir f ti l t t [ , , ].
it ri l fi i f i r criti l l i t t t occ r to aintai itoc ri l
f cti when cells are exposed to a wide array of metabolic and environmental stresses [140,141,143].
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This includes maintaining mitochondria biomass, number, biogenesis, and their degradation (Figure 3).
When fission is unopposed, mitochondrial fragmentation occurs, and is associated with excess glucose
abundance, severe stress, cellular death, and impaired OXPHOS. However, fission has also been
observed to be vital in the generation of new mitochondria (mitochondrial biogenesis), alongside a
quality control process to remove old defective mitochondria, ensuring proper mitochondrial function
(Figure 3) [140,141].
Unopposed mitochondrial fusion is observed in mitigating stress during nutrient withdrawal
and enhancing OXPHOS rates. This occurs by removing defective mitochondria via the fusing with
functionally healthy mitochondria in a complementation process [140,141] (Figure 3). There is some
evidence that mitochondrial fission and fusion are regulated by p53: Mitofusin2 (mfn2), an integral
membrane bound component of fusion, has been shown to be a direct downstream target of p53,
implicated in stopping cellular proliferation and sensitizing cell death [57,140].
Within muscle physiology studies, p53 has been observed to regulate alterations in fission
and fusion proteins, with p53 knockout (KO) mice displaying acute alterations in mitochondrial
morphology and reduced respiratory capacity [58]. This coincided with a former study revealing a
loss of mitochondrial function and biomass in p53 KO mice, while wild-type p53 mice maintained
mitochondrial biogenesis [142]. The influence of p53 in mitochondrial dynamics is yet to be investigated
in breast cancer metabolism, alongside the pivotal role of p53 in mediating the balance between
glycolysis and OXPHOS, a current focus in our laboratory. This may prove vital as mitochondrial
dynamics appear to serve key metabolic roles towards changing metabolic demands and bioenergetic
efficiency of the cell.
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3.5. p53 Family Members p63 and p73 Play Significant Roles in the Cancer Metabolic Switch
While this review is focused on the functions of the major p53 isoform, some of the smaller
alternatively spliced p53 isoforms have been shown to enhance p53 target expression or inhibit p53
wild-type function [145], especially in breast cancer [146]. Two other p53 family members, p63 and
p73, also modulate p53 function [4]. Although p53, p63, and p73 isoforms are highly homologues,
sharing similar structure and functions as transcriptional factors, studies in KO models of p53, p63,
and p73 show functional diversity as well as overlapping functions [147–151]. Interestingly, akin to
p53, recent studies show that p63 and p73 isoforms (TAp63, ∆Np63, Tap73, and ∆Np73) partake
in glucose metabolism [4]. However, this shared relationship proves to be divided, as p63 and p73
isoforms exhibit effects both similar and opposite to those of p53. Whereas p53 is known to inhibit
glycolysis and induce fatty acid oxidation, TAp63-null mice develop associated defects in glucose
uptake, leading to insulin resistance, obesity, and glucose intolerance. Moreover, although controversy
over p53’s roles in the phosphate pentose pathway (PPP) lingers, TAp73 appears to enhance PPP flux
through increasing the expression of glucose-6-phosphate dehydrogenase, therefore supporting cancer
proliferation [152].
As mentioned, p63 and p73 do exhibit similar effects or share overlapping functions with p53.
These include TAp63 and TAp73’s ability to inhibit glycolysis; the function is similar to that of p53,
although the mechanisms vary. Both TAp63 and TAp73 have been shown to induce islet amyloid
polypeptide to inhibit glycolysis via inhibiting HK2 [153]. The TAp63 isoform, akin to p53, is associated
with inducing GLS2, therefore promoting the TCA cycle [154]. TAp73 is associated with supporting
mitochondrial function via oxygen consumption and complex IV stability [155]. This aligns nicely
with recent evidence of p53’s role in mitochondrial function, as reviewed in [4]. Collectively, p63 and
p73 isoforms’ effects on glycolysis are influenced by the cellular environment, although they both seem
to promote the TCA cycle and PPP.
4. p53 and Breast Cancer Metabolism
Breast cancer metabolism is diverse and very much dependent on hormone fluctuation [156].
Metabolic rewiring is also determined by breast cancer subtypes [157]. Mutations in p53 have been
identified as drivers of aberrance in oxidative respiration and glycolysis in breast cancer, also dependent
on the breast cancer sub-type [156,157]. Contrary, most hormone-dependent post-menopausal breast
cancers, which make up the major breast cancer sub-type, have wt-p53. p53 plays a complex role in
normal breast and breast cancer metabolism, complicated by the constant flux of female hormones,
as reviewed in [9]. In breast cancer, p53 has been associated with the modulation of key proteins in
mitochondrial metabolism, cytochrome c oxidase 2 synthesis, and the TP53-induced glycolysis and
apoptosis regulator (TIGAR) [158]. Targeting p53 in its role as a metabolic switch is an exciting but
underexplored area of breast cancer treatment. In fact, drugs that target the p53-dependent metabolic
checkpoint such as metformin (a commonly used medication for type 2 diabetes to reduce glucose
production) are undergoing clinical trials in combination with established therapies [159].
4.1. Upstream Regulation and Reactivation of p53 in Breast Cancer
As mentioned in Section 1.2, only 20–30% of breast cancers sustain TP53 mutations, leaving
~70% retaining functional wild-type-p53 (wt-p53) [43,44]. Under homeostatic conditions, cellular p53
protein levels are low due to its short half-life and continual degradation by the HDM2 ubiquitin
ligase [160,161]. Due to the large proportion of breast carcinomas retaining wt-p53, radiotherapy and
chemotherapy agents such as doxorubicin are successful in reactivating p53 via the DNA damage
pathway, inducing cell cycle arrest and cell death [25–27]. In line with its classical role as a tumor
suppressor, novel anti-HDM2 (human double minute 2) agents target HDM2, stabilize p53, and
reactivate the p53 signaling pathway to kill cancer cells [27,162–164]. Nutlin-3a is one such chemical
repressor; by binding HDM2, nutlin 3a reduces HDM2 function, thus stabilizing p53, and has been
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found to be efficacious in both in vivo and in vitro models, including breast cancer. It is currently
undergoing phase III clinical trials [162–165].
p53 is commonly silenced in breast cancer by loss of upstream/downstream mechanisms. A key
natural, endogenous regulator of p53 is the tumor suppressor p14 alternative reading frame (p14ARF).
The p14ARF protein is an upstream positive regulator of p53 through its binding to HDM2 and
preventing p53 degradation, thus stabilizing p53 expression and activating p53 function [166–168]
(Figure 4).Cancers 2018, 10, x 12 of 21 
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Figure 4. The p14ARF-p53 pathway. HDM2 sustains low basal levels of p53 by its continuous
degradation [160,161]. p14ARF, activated by cellular stress signals and potentially regulated by estrogen
and progesterone hormones in the breast [93,168–171], causes inhibition of the HDM2–p53 complex,
therefore stabilizing p53. p53 is able to bring about cell cycle arrest at the G1/S phase through the
activation of the CDK inhibitor p21, which inhibits downstream CDK 4 and 6 [66,68,69]. Both CDK 4
and 6 are well-known mediators of G1/S cell cycle progression, hence their inhibition by p21 halts the
cell cycle [66].
p14ARF is activated in response to adverse environmental stimuli to prevent hyperproliferation
of cells to prevent cancer. The upstream p53 regulator, p14ARF, is silenced by methylation, deletion,
or mutation in many breast cancers [166,172,173]. As such, therapeutic interest in re-activating the
p14ARF-p53 pathway via re-introducing p14ARF or utilizing p14ARF mimetics to induce p53 (such as
Nutlin-3a) has gained momentum. Early studies into re-activating the p14ARF-p53 pathway within
breast cancer cells revealed rapid induction of apoptosis. However, these models utilized an adenoviral
vector system expressing high, non-physiologically relevant levels of p53 [174]. Our laboratory
has developed an inducible vector system to express controlled, physiologically relevant levels of
p14ARF to activate the p53 signaling pathway in hormone-dependent breast cancer cells [59,93].
These studies demonstrated that p14ARF induces the p53-p21-retinoblastoma (Rb) pathway to induce
cell cycle arrest; however, the cells did not undergo apoptosis, but remained metabolically active and
viable [59,93]. Our studies linked the activation of p14ARF-p53 signaling directly to changes in breast
cancer cellular metabolism.
4.2. p53 Regulates Mitochondria Dynamics in Breast Cancer
Although mitochondrial dynamics has been observed to be influenced by p53 (Section 3.4), there is
very little understanding of this process in breast cancer. In breast cancer, as in most cancers, p53 is
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reactivated by chemotherapy or radiation therapy to induce mitochondria-mediated cell death or
permanent cell cycle arrest (Section 2.1). In our studies, in the absence of external stress factors, p14ARF
re-activation of the p53 pathway rapidly induced cell cycle arrest (within 6 h) in breast cancer cells.
Instead of the expected classical p53–mitochondria-induced apoptosis, p53 promoted major metabolic
reprogramming in hormone-dependent breast cancer cells in favor of increased cellular function
and viability [59,93]. Mitochondrial biomass, membrane potentiality, and mitochondria activity were
enhanced, as well as metabolic and cellular morphological changes [59,93]. Therefore, p53 may be
regarded as a pendulum between mitochondrial survival on one hand and mitochondrial-induced
cell death on the other, depending on the cellular environment. Reactivation of the p14ARF-p53
pathway in ER+ breast cancer cells did not overtly alter the p53-dependent annexin A5 apoptotic
marker associated with mitochondria-mediated cell death [59,93,94]. However, expression of other
annexin family members and associated proteins, which control calcium flux, were enhanced [59,93,94].
Our findings supported the role of p53 as a key orchestrator of annexin/S100A regulation. In this
study, annexins A1, A2, A4, A6, and A9 were upregulated downstream of the p53 signaling
pathway [94]. Although the consequences of p53 differential regulation of the annexins/S100A
family is not clear, intracellular calcium homeostasis and regulation of mitochondria function are
not mutually exclusive [175]. For example, A6 has been reported to be an important protein in
the regulation of mitochondrial morphogenesis, fission, and fusion, and loss of A6 expression is
associated with fragmented mitochondria and impaired membrane potentiality and impaired oxidative
respiration [176]. Regulation of calcium signaling is essential for mammary gland function and
deregulation of calcium homeostasis is associated with cancer pathophysiology.
This p53-attenuated apoptosis aligns nicely with a series of studies, illustrating that the
estrogen receptor (ERα) interacts with p53, leading to an intrusion in p53 downstream signaling
targets [177–179]. ERα signaling pathways and its expression within cancer and normal breast
physiology have been extensively documented [180–182]; however, the interaction between ERα
and p53 is novel within breast cancer. Konduri and colleagues first observed that p53 and ERα interact
directly, leading to the downregulation of p53 alongside its downstream signaling targets such as
p21 [178]. Further investigations by Brown and colleagues confirmed this interaction and showed
that repression of p53 by ERα led to a lack of repression of genes involved in resisting apoptosis,
thus hindering the ability of p53 to prompt apoptosis [177]. The data suggest a mechanism of resistance
to treatments mediated through ERα, whereby functionally active p53 can become repressed in ER+
breast cancers. This also begs the question, does p53 interaction with ER+ in normal breast physiology
to prevent cell death and divert the course of metabolic function?
4.3. Novel Avenues for Targeting p53 in Drug Resistance, Recurrence, and Metastasis in Breast Cancer
Increasing evidence supports the notion that dysregulated metabolism confers drug resistance and
recurrence in breast cancer [156]. Breast cancer cells, like most cancer cells, use glucose and glutamine to
survive, so, conceptually, targeting the energy-related metabolic pathways for therapeutic intervention
in breast cancer is an exciting idea [183]. However, there is a fine balance between p53 regulation of
mitochondrial processes, cell death, or cell survival in normal and cancer tissues. Therefore, targeting
metabolism to prevent breast cancer recurrence has inherent problems: (1) All normal and cancer cells
utilize both glycolysis and oxidative respiration for energy requirements; (2) different sub-types of
breast cancer have different metabolic requirements and p53 status; (3) the complexities associated
with the constant changes in breast metabolism and the emerging cross-talk of p53 with hormone
receptors and other signaling pathways. This requires a more in-depth understanding of the intricacies
of p53’s influence on metabolism in normal and breast cancer cells.
An interesting advancement in our understanding of maladaptive metabolism and cancer came
from studies in exercise physiology. Exercise, which alters cellular metabolism, has long been known to
reduce breast cancer risk [184]. Aerobic exercise has long been known to increase mitochondria function
and lactate clearance, and as well as to decrease glycolysis [185]. Lactate, once considered a waste
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product of anaerobic metabolism, is now regarded as an important fuel for cancer cell development
and metastasis [186]. In addition, aerobic exercise has been shown to increase fat oxidation [187]
As demonstrated in skeletal muscle, during exercise, p53 is a key molecule in substrate metabolic
regulation and exercise-induced mitochondrial biogenesis, thus increasing mitochondrial respiratory
activity [188]. As mentioned in Section 3.4, p53 regulates alterations in fission and fusion proteins,
maintaining mitochondria morphology and respiratory capacity in muscle [58]. Perhaps a clearer
understanding of the effects of exercise on p53-cellular metabolic reprogramming may provide clues
for the prevention of breast cancer and new avenues for breast cancer treatment options.
5. Conclusions
The studies highlighted in this review reveal that p53 has a plethora of functions in normal and
cancer metabolism beyond the classical mitochondrial death syndrome. Our major research focus is
on understanding hormone-dependent cancer origin, treatment resistance, and recurrence in breast
cancer. It is important to understand the role of p53 in the regulation of cancer metabolism as well as
its underlying mechanism and how it applies directly to breast cancer. The mitochondrial targets of
p53 that are unfolding would provide a platform to further investigate the role of p53 in modulating
mitochondrial metabolic pathways. Future studies would include confirming p53 interactions with the
aforementioned mitochondrial proteins, along with formulating a cohesive timeline for the changing
metabolic phenotypes associated with p53’s evolving role as a master metabolic regulator in normal
mammary cells and breast cancer cell evolution.
The ultimate goal will be to elucidate the metabolic functions of p53 within breast cancer
metabolism, which will reveal critical metabolic hotspots that cancers advantageously re-engineered
for sustenance. Full understanding of these events would pave the way for the development of novel
therapeutics targeting breast cancer metabolism and eventually new strategies to fight breast cancer.
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